Kazia Therapeutics has announced a significant development in its quest to advance paxalisib, a promising treatment for newly diagnosed glioblastoma multiforme, as the FDA has agreed to a Type C meeting in December 2024 to discuss its potential registration pathways.
Kazia Therapeutics has announced a significant development in its quest to advance paxalisib, a promising treatment for newly diagnosed glioblastoma multiforme, as the FDA has agreed to a Type C meeting in December 2024 to discuss its potential registration pathways.
2025中に承認されるといいね。
投資の参考になりましたか？